Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...
THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...
Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results